The robotic catheterisation systems market is experiencing a development in terms of digitalisation of instruments with it being a main factor in the advancement of automated and integrated cardiovascular interventional labs. The developments in robotic technology are occurring at a rapid pace, which would assist hospitals in cutting down on catheterisation lab costs, chiefly in inaccessible and isolated areas. Using the findings from Future Market Insights report, ‘Robotic Catheterisation Systems Market’, Sabyasachi Ghosh, Associate Vice President at Future Market Insights, dives into the study.
The global sales of robotic catheterisation systems are estimated to be worth US$54.4 million in 2025 and anticipated to reach a value of US$190.2 million by 2035. Sales are projected to rise at a CAGR of 13.3% over the forecast period between 2025 and 2035. The revenue generated by robotic catheterisation systems in 2023 was US$42.0 million.
Key industry highlights
Long-term cost efficiency of robotic catheterisation systems demanded in the markets
While the initial costs of robotic catheter systems may be steep, economically, they are much more efficient in the long-run. These high-tech systems are associated with faster and more accurate procedures that lead to a direct decrease in procedure times and enhance patient outcomes.
This, in turn, leads to shorter less costly hospital stays. Robotic systems also minimise the risk of complications and human error, which may result in cost related to treatment and recovery for the patient. These systems, through greater accuracy in catheter placement and reduced rates of adverse events, significantly reduce the need for secondary surgical interventions, thus minimising hospitalisations and other medical interventions.
Further, accuracy improves such clinical outcomes as readmissions and re-hospitalisations, which decreases overall increment in costs of healthcare. Over time, the financial advantages of operational efficiencies and better patient outcomes arising from robotic systems make it a capital-efficient investment toward the healthcare institutions. This is prompting hospitals into realising the long-term financial benefits of robotic catheterisation technology.
Enhanced precision and safety with robotic catheterisation systems driving the demand
Such robotic-assisted procedures, whereby precision, dexterity and control over catheterisation are maximised, produce satisfactory patient results-and a better chance of success for doctors involved. Although this technology does have the potential to put surgeons at ease during potentially challenging procedures, it has also greatly reduced human error opportunities through enhanced accuracy.
Highly controlled precision placement means that catheters get in just where they need to be, resulting in fewer complications and increased chances of success. Moreover, robotic systems reduce dependence on manual adjustments that, among other things, may contribute to error or duplication of technique.
Besides better control over precision, robotic systems minimise radiation exposure, a frequent concern in conventional catheterisation procedures. By offering better control of the whole procedure, in conjunction with real-time imaging, the amount of fluoroscopy required is reduced, consequently cutting the radiation dose for patients. Such benefits, therefore, translate into safer procedures, which consequently lessen the risk of side effects related to radiation exposure.
Reducing radiation risks and enhancing precision will create opportunities in the market
The opportunistic approach to this market is driven by the factor of reduced risk in terms of occupational hazards with reference to radiation exposure for cardiologists. During the interventional cardiology procedures, it has been reported by majority of surgeons that the occupational hazards associated with interventional cardiology procedures affected them.
The modern cath labs use ionising radiation comprehensively in the form of X-rays, which is responsible for the practitioners to be exposed to risk of malignancy also comprising the neck and head region.
Though the preventive measures, such as the utilisation of lead aprons may reduce the impact of such risk associated factors, it is to be noted that their long term use may be associated with the development of orthopaedic injuries among practitioners.
The market for robotic catheterisation systems is thus set to witness a lucrative growth with the advancement in technology as well as the extensive testing of these systems in clinical trials for their efficacy.
Challenges in adopting robotic catheterisation systems for peripheral vascular interventions
The restricted mechanical capacity of balloon angioplasty in peripheral vascular interventions to recover calcified lesions has given rise to the development of novel technologies using robot assisted catheterisation procedures. Conventionally, large number of robot-assisted catheterisation technologies have been established to assist with the physicians’ ability to operate with percutaneous coronary intervention procedures.
However, there lacks data comparing the endovascular options and thus, there is large parity with regard to establishing which robot assisted catheterisation procedure would benefit the patient, depending upon the disease and procedural impact on surgical outcomes.
Additionally, the high upfront cost of robotic catheterisation systems depicts a negative impact on the end users’ decision to purchase them. Setting robot-assisted endovascular procedures as standard of care may take time since special reimbursement for robotic assisted catheterisation are not available.
The lack of studies demonstrating cost effectiveness and outcome data from manufacturers might make it challenging for care centres to justify investing in the robotic platform. By extending the spectrum of indications for robotic catheterised procedures, manufacturers may improve their applicability and potentially gain market share in the long term.
Other major complications include infection at the insertion site of the robotic catheterisation systems guiding wire and catheter, contamination of the burr catheter and seeding of the catheter.
Regional insights
United States dominates market: Driven by aging population and technological innovation
The United States has a stronghold in the North American market for robotic catheterisation systems in 2024, and growth is expected throughout the forecast period. High disability and ageing populations drive demand for advanced medical technologies.
Robust growth of the market in China driven by healthcare expansion
In 2024, China was the dominant player in the East Asia market. The major driver is the increasing adoption of automation and robotic assistive devices in the healthcare sector, with China being one of the major contributors to the development of robotic systems for various medical applications, including catheterisation procedures. Increasing elderly population and the rising tone of cardiovascular diseases provide a wider space for growth for advanced medical technologies in the country.
Strong growth driven by advanced medical technologies and healthcare investments in UK
The UK market for robotic catheterisation systems will grow at a CAGR of about 10.3% during the forecast period. This growth could be attributed to an increasing burden of disease in the region, which is augmenting the demand for advanced medical technology. The broad acceptance of clinically approved mechanical and automated systems for emergency surgeries has further awoken the UK market.
Market concentration
Market leaders such as Siemens Healthineers and Johnson and Johnson (by Hansen Medical, Inc.), with a broad range of products, worldwide presence and notable investments in research and development, these companies are seen to lead in innovation. Thus, having a significant bearing on market trends, these companies set benchmarks for technology and clinical outcomes.
The Tier 2 players are firms like Stereotaxis, Inc., who offer rather specific contributions with their robotic navigation and catheterisation systems. Usually, specialisation and niche applications are adopted by these companies to evolve their technology differentiations and target solutions to carve their market share. Their contribution undoubtedly fills out the market, catering to specialised clinical needs.
Tier 3 consists of small or emerging firms that cover those territories within themselves or address some specific innovations of note. Usually, the Tier 3 players operate on a very small scope, offering bespoke solutions or cost-effective choices to gain market share.
The pyramidal structure shows a dynamic market where the well-networked large powers generate growth that is supplemented with the innovation from mid-sized companies to satisfy specialised or underexplored market niches by small players.
Find the full report here: Robotic Catheterisation Systems Market by Future Market Insights.
